BioSpace News Archive

PacBio announced that it will hold its quarterly conference call to discuss its third quarter 2022 financial results on Monday, Nov. 7, 2022, at 5:00 p.m. Eastern Time.

Prelude Corporation today announced study results demonstrating that DCISionRT provides patients with ductal carcinoma in situ (DCIS) superior risk and RT benefit prediction compared to common clinicopathologic features.

NuGen Medical Devices Inc., a leader in needle-free drug delivery, is pleased to announce that it has signed a distribution agreement with Science - Link Trading, a company whose mission it is to help bring new disruptive technologies to market.

NuVasive, Inc. announced today the Company will release its third quarter financial results on Wednesday, November 9, 2022, after the market close.

Milestone Pharmaceuticals Inc. today announced that data from the Phase 3 RAPID clinical trial of self-administered etripamil in patients with paroxysmal supraventricular tachycardia (PSVT) in the at-home setting will be featured during a Late-Breaking Clinical Trials session at the American Heart Association Scientific Sessions 2022 taking place November 5-7, 2022 in Chicago, IL and virtually.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, has named life sciences veteran Jieun Choe as chief marketing officer (CMO).

Marinus Pharmaceuticals, Inc. today announced that it plans to release financial results for the third quarter ended September 30, 2022 before the U.S. financial market opens on November 8, 2022.

Modifi Biosciences has been selected by the National Cancer Institute for a Fast-Track Small Business Innovation Research Award of $2.4 million to further advance its novel precision oncology platform into the clinic.

Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”) (NASDAQ: ALHC), a tech-enabled Medicare Advantage company, today announced that John Kao, founder and CEO, and Thomas Freeman, chief financial officer, will participate in the Credit Suisse 31st Annual Healthcare Conference.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) today announced that it will present full data from the Phase 2 clinical trial evaluating setmelanotide in hypothalamic obesity during The Obesity Society’s ObesityWeek® 2022.